E-mail: razga.filip@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ARE MUTATIONS IN THE IDH2 GENE SUITABLE MOLECULAR MARKERS FOR MRD MONITORING IN AML PATIENTS?
- CEBPA GENE MUTATIONAL STATUS: A COMPLETE SCREENING USING HIGH-RESOLUTION MELT CURVE ANALYSIS
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- IMATINIB (IMA) PLASMA CONCENTRATION (PC) MONITORING AND ITS CORRELATION WITH TREATMENT RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA (CML): A SINGLE CENTRE EXPERIENCE
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCRABL1 KINASE DOMAIN MUTATIONS
- MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
- NEUROMUSCULAR TOXICITY OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
- SKIN ADVERSE EFFECTS OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA – SINGLE CENTRE EXPERIENCE
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- THE PROSPECTIVE ANALYSIS OF LOW LEVEL BCR-ABL1 T315I MUTATION IN THE CD34+ CELLS OF DE NOVO CML PATIENTS
- TREATMENT OF MOLECULAR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
